AVROBIO, Inc. to Present at Chardan’s 3rd Annual Genetic Medicines Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVROBIO, Inc. (NASDAQ:AVRO), a Phase 2 clinical-stage gene therapy company, today announced that Geoff MacKay, President and CEO of AVROBIO, will present at Chardan’s 3^rd Annual Genetic Medicines Conference on Monday, October 7, 2019.

Chardan's 3^rd Annual Genetic Medicines Conference
Date: Monday, October 7, 2019
Time: 3:45 p.m. ET
Location: The Westin Grand Central Hotel, New York, NY

A live webcast of the presentation will be available on the investors section of the AVROBIO company website at www.avrobio.com. After the live webcast, the event will remain archived on the AVROBIO website for 90 days.

About AVROBIO, Inc.

AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. The Company’s plato™ platform includes a proprietary vector system, automated cell manufacturing solution and refined conditioning regimen deploying therapeutic drug monitoring. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON. For additional information, visit www.avrobio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191003005189/en/